AAAAAA
Results:
1-15
|
Results: 15
Authors:
Streckfus, C
Bigler, L
Dellinger, T
Dai, XL
Cox, WJ
McArthur, A
Kingman, A
Thigpen, JT
Citation: C. Streckfus et al., Reliability assessment of soluble c-erbB-2 concentrations in the saliva ofhealthy women and men, ORAL SURG O, 91(2), 2001, pp. 174-179
Authors:
Thigpen, JT
Citation: Jt. Thigpen, Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer? The Markman article reviewed, ONCOLOGY-NY, 15(1), 2001, pp. 104-105
Authors:
Streckfus, C
Bigler, L
Dellinger, T
Dai, XL
Kingman, A
Thigpen, JT
Citation: C. Streckfus et al., The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: A preliminary study, CLIN CANC R, 6(6), 2000, pp. 2363-2370
Authors:
Streckfus, C
Bigler, L
Tucci, M
Thigpen, JT
Citation: C. Streckfus et al., A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor,cathepsin-D, and p53 in saliva among women with breast carcinoma, CANCER INV, 18(2), 2000, pp. 101-109
Authors:
Thigpen, JT
Citation: Jt. Thigpen, Chemotherapy for advanced ovarian cancer: Overview of randomized trials, SEMIN ONCOL, 27(3), 2000, pp. 11-16
Authors:
Herrin, VE
Thigpen, JT
Citation: Ve. Herrin et Jt. Thigpen, Chemotherapy for ovarian cancer: Current concepts, SEM SURG ON, 17(3), 1999, pp. 181-188
Authors:
du Bois, A
Neijt, JP
Thigpen, JT
Citation: A. Du Bois et al., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?, ANN ONCOL, 10, 1999, pp. 35-41
Authors:
Brady, MF
Thigpen, JT
Vermorken, JB
Parmar, MKB
Citation: Mf. Brady et al., Randomised trials in ovarian cancer: trial design considerations, ANN ONCOL, 10, 1999, pp. 75-82
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
Thigpen, JT
Brady, MF
Alvarez, RD
Adelson, MD
Homesley, HD
Manetta, A
Soper, JT
Given, FT
Citation: Jt. Thigpen et al., Oral medroxyprogesterone acetate in the treatment of advanced or recurrentendometrial carcinoma: A dose-response study by the Gynecologic Oncology Group, J CL ONCOL, 17(6), 1999, pp. 1736-1744
Authors:
Hensley, ML
Schuchter, LM
Lindley, C
Meropol, NJ
Cohen, GI
Broder, G
Gradishar, WJ
Green, DM
Langdon, RJ
Mitchell, B
Negrin, R
Szatrowski, TP
Thigpen, JT
Von Hoff, D
Wasserman, TH
Winer, EP
Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Authors:
Thigpen, JT
Citation: Jt. Thigpen, Limited-stage ovarian carcinoma, SEMIN ONCOL, 26(6), 1999, pp. 29-33
Authors:
Herrin, VE
Thigpen, JT
Citation: Ve. Herrin et Jt. Thigpen, High-dose chemotherapy in ovarian carcinoma, SEMIN ONCOL, 26(1), 1999, pp. 99-105
Authors:
Patel, MS
Thigpen, JT
Vance, RB
Elkins, SL
Guo, M
Citation: Ms. Patel et al., Basal cell carcinoma with lung metastasis diagnosed by fine-needle aspiration biopsy, SOUTH MED J, 92(3), 1999, pp. 321-324
Authors:
Rose, PG
Bundy, BN
Watkins, EB
Thigpen, JT
Deppe, G
Maiman, MA
Clarke-Pearson, DL
Insalaco, S
Citation: Pg. Rose et al., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N ENG J MED, 340(15), 1999, pp. 1144-1153
Risultati:
1-15
|